Curanex Pharmaceuticals, Inc. Expands Pipeline to Target Cancer Cachexia, Addressing Major Oncology Supportive-Care Gap

Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (&...

April 07, 2026 | Tuesday | News
FDA Extends EYLEA HD Dosing Interval to 20 Weeks, Advancing Long-Term Retinal Care

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with exte...

April 07, 2026 | Tuesday | News
OneCyte and Kemp Proteins Partner to Transform Cell Line Development

OneCyte, a leader in high-throughput single-cell analysis and cell line development technologies, and Kemp Proteins, a pioneer in protein engineering and...

April 06, 2026 | Monday | News
Canada Invests $79M in Aspect Biosystems to Fast-Track Cellular Therapies for Chronic Diseases

Government investment will accelerate clinical development and strengthen Aspect’s advanced biomanufacturing capabilities for its bioengineered c...

April 06, 2026 | Monday | News
Thermo Fisher Scientific Launches Automated CTS Compleo System To Streamline Cell Therapy Fill And Finish

Thermo Fisher Scientific Inc., the world leader in serving science,  announced the global launch of the Gibco™ CTS™ Compleo™ Fill ...

April 03, 2026 | Friday | News
Reprogramming the Tumor: Lew Bender on Engineering a New Paradigm in Cancer Therapy

From a basement-born idea to a publicly traded biotech advancing late-stage clinical trials, Lew Bender’s journey reflects both scientific persistenc...

April 02, 2026 | Thursday | Interaction
Thermo Fisher Scientific Launches Next-Generation CHOvantage™ GS Platform to Accelerate Biologics Development Timelines

Thermo Fisher Scientific Inc., the world leader in serving science,  announced a next-generation, integrated cell line development platform that ena...

April 02, 2026 | Thursday | News
ORIC Advances Rinzimetostat To Phase 3 With Strong Efficacy And Safety In Prostate Cancer

Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone...

April 02, 2026 | Thursday | News
Lilly To Acquire Centessa Strengthening OX2R Pipeline For Sleep Wake Disorders

Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa’s OX2R agonist pip...

April 02, 2026 | Thursday | News
Galapagos Partners with Gilead to Advance T Cell Engager Gamgertamig in Autoimmune Diseases

New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos  Following this transaction, the Company w...

April 01, 2026 | Wednesday | News
Avacta Doses First Patient in FOCUS-01 Trial of AVA6103, Advancing Tumor-Targeted Oncology Platform

Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers Initial data from the trial expected later this ye...

April 01, 2026 | Wednesday | News
Biogen to Acquire Apellis in $5.6B Deal to Strengthen Immunology and Rare Disease Portfolio

Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including...

April 01, 2026 | Wednesday | News
4basebio Expands UK Footprint With New Cambridge Innovation and Manufacturing Hub

4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces a significant expansio...

April 01, 2026 | Wednesday | News
Biocytogen Signs Platform License Agreement with Taisho Pharmaceutical

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and develo...

March 31, 2026 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2026 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close